CU23288B7 - DERIVADOS DE TROPANO ÃsTILES EN TERAPIA - Google Patents

DERIVADOS DE TROPANO ÃsTILES EN TERAPIA

Info

Publication number
CU23288B7
CU23288B7 CU20020243A CU20020243A CU23288B7 CU 23288 B7 CU23288 B7 CU 23288B7 CU 20020243 A CU20020243 A CU 20020243A CU 20020243 A CU20020243 A CU 20020243A CU 23288 B7 CU23288 B7 CU 23288B7
Authority
CU
Cuba
Prior art keywords
optionally substituted
tropanic
therapy
derivatives
preparation
Prior art date
Application number
CU20020243A
Other languages
English (en)
Inventor
Anthony Wood
Manoussos Perros
Blanda Luzia Christa Stammen
David Anthony Price
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0014046A external-priority patent/GB0014046D0/en
Priority claimed from GB0015835A external-priority patent/GB0015835D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of CU23288B7 publication Critical patent/CU23288B7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)

Abstract

La presente invención proporciona compuestos de fórmula ESPACIO PARA FÃ"RMULA en la que R1 es un cicloalquilo C3-6 opcionalmente sustituido con uno o más con uno o más átomos de fllúor, o cicloalquil (C3--6)metilo opcionalmente sustituído en el anillocon uno o más átomos de flúor; y R2 es un fenilo opcionalmente sustituido con uno o más átomos de flúor; sales y solvatos farmacéuticamente aceptables de éstos, y procedimientos para su preparación, intermedios utiizados en su preparación, composiciones que los contienen y usos de dichos compuestos.</P>
CU20020243A 2000-05-26 2002-10-28 DERIVADOS DE TROPANO ÃsTILES EN TERAPIA CU23288B7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0014046A GB0014046D0 (en) 2000-05-26 2000-05-26 Compounds useful in therapy
GB0015835A GB0015835D0 (en) 2000-06-27 2000-06-27 Compounds useful in therapy

Publications (1)

Publication Number Publication Date
CU23288B7 true CU23288B7 (es) 2008-06-30

Family

ID=26244452

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20020243A CU23288B7 (es) 2000-05-26 2002-10-28 DERIVADOS DE TROPANO ÃsTILES EN TERAPIA

Country Status (50)

Country Link
EP (3) EP1990341B1 (es)
JP (2) JP3693957B2 (es)
KR (2) KR100548854B1 (es)
CN (2) CN1279040C (es)
AP (1) AP1965A (es)
AR (2) AR028622A1 (es)
AT (2) ATE260914T1 (es)
AU (2) AU2001252482B2 (es)
BG (1) BG65966B1 (es)
BR (1) BRPI0110955B8 (es)
CA (1) CA2408909C (es)
CR (1) CR10145A (es)
CU (1) CU23288B7 (es)
CY (3) CY2008006I2 (es)
CZ (1) CZ299102B6 (es)
DE (3) DE60135685D1 (es)
DK (2) DK1284974T3 (es)
DZ (1) DZ3464A1 (es)
EA (2) EA005382B1 (es)
EE (1) EE05110B1 (es)
EG (1) EG24137A (es)
ES (3) ES2401812T3 (es)
FR (1) FR08C0007I2 (es)
GE (1) GEP20063799B (es)
HR (1) HRP20020938B1 (es)
HU (1) HU225810B1 (es)
IL (2) IL152531A0 (es)
IS (1) IS2511B (es)
LT (1) LTC1284974I2 (es)
LU (1) LU91417I2 (es)
MA (1) MA26902A1 (es)
ME (1) ME00555A (es)
MX (1) MXPA02011631A (es)
MY (3) MY156920A (es)
NL (1) NL300338I2 (es)
NO (3) NO327892B1 (es)
NZ (1) NZ521477A (es)
OA (1) OA12264A (es)
PA (1) PA8517101A1 (es)
PE (1) PE20011371A1 (es)
PL (1) PL200551B1 (es)
PT (2) PT1526134E (es)
RS (2) RS50904B (es)
SI (2) SI1526134T1 (es)
SK (1) SK286129B6 (es)
TN (1) TNSN01077A1 (es)
TR (1) TR200400541T4 (es)
TW (1) TWI230160B (es)
UY (1) UY26727A1 (es)
WO (1) WO2001090106A2 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020938B1 (en) * 2000-05-26 2011-05-31 Pfizer Inc. Tropane derivatives useful in therapy
CA2450271A1 (en) * 2001-06-12 2002-12-19 Sk Corporation Novel phenylalkyl diamine and amide analogs
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
SE0200919D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Chemical compounds
GB0208071D0 (en) * 2002-04-08 2002-05-22 Pfizer Ltd Tropane derivatives useful in therapy
RS51550B (sr) * 2002-04-08 2011-06-30 Pfizer Inc. Derivati tropana kao modulatori ccr5
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
BR0309982A (pt) * 2002-05-23 2005-03-22 Pfizer Método para identificação de um ligando, pelo qual o tempo de residência no receptor é medido
ES2311755T3 (es) * 2002-12-13 2009-02-16 Smithkline Beecham Corporation Compuestos de ciclohexilo como antagonistas de ccrs.
SE0301369D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
DE10336274A1 (de) * 2003-08-07 2005-03-10 Honeywell Specialty Chemicals Verfahren zur Herstellung von geminalen Difluoralkanen
US7825147B2 (en) 2003-08-29 2010-11-02 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
EP1786816A4 (en) 2003-09-10 2009-11-04 Virochem Pharma Inc SPIROHYDANTOIN COMPOUNDS AND METHODS FOR MODULATING CHEMOKINE RECEPTOR ACTIVITY
MXPA06003749A (es) * 2003-10-03 2006-06-14 Pfizer Derivados de tropano.
TW200610761A (en) * 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
DK1761542T3 (da) 2004-06-09 2008-04-28 Hoffmann La Roche Octahydropyrrolo[3,4-C] pyrrolderivater og anvendelsen deraf som antivirusmidler
CA2586231A1 (en) * 2004-11-19 2006-05-26 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and uk-427, 857
WO2006064340A2 (en) * 2004-12-13 2006-06-22 Pfizer Limited Process for the preparation of n-acyl beta-aminoaldehydes
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
KR20080035653A (ko) 2005-07-22 2008-04-23 프로제닉스 파머슈티컬스, 인코포레이티드 Hiv―1 감염 환자에서 바이러스 부하를 감소시키는방법
EP1940781A1 (en) 2005-10-19 2008-07-09 F.Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
WO2007144720A2 (en) * 2006-06-12 2007-12-21 Pfizer Products Inc. Ccr5 antagonist for enhancing immune reconstitution and treating opportunistic infection in hiv patients
EP2057125B1 (en) 2006-08-16 2011-03-30 F. Hoffmann-La Roche AG Non-nucleoside reverse transcriptase inhibitors
WO2008063600A2 (en) * 2006-11-17 2008-05-29 Concert Pharmaceuticals Inc. Triazolyl tropane derivatives
MX2009005881A (es) 2006-12-13 2009-06-12 Hoffmann La Roche Derivados de 2-(piperidin-4-il)-4-fenoxi o fenilamino-pirimidina como inhibidores de la transcriptasa inversa no nucleosida.
US20080146605A1 (en) * 2006-12-19 2008-06-19 Auspex Pharmaceuticals, Inc. Preparation and utility of ccr5 inhibitors
US20080207659A1 (en) 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
WO2008132128A2 (en) * 2007-04-27 2008-11-06 Solvay (Société Anonyme) Synthesis of a pharmaceutically active compound
RU2368613C1 (ru) * 2008-02-19 2009-09-27 Институт молекулярной генетики Российской Академии наук (ИМГ РАН) (Статус Государственного учреждения) Равномерно меченный тритием 4,4-дифтор-n-{(1s)-3-[3-(3-изопропил-5-метил-4н-1,2,4-триазол-4-ил)-8-азабицикло[3.2.1]окт-8-ил]-1-фенилпропил}циклогексан карбодиимид
CA2716838C (en) * 2008-02-29 2014-01-07 Schering Corporation Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same
CN101712679B (zh) * 2008-10-08 2013-04-10 中国科学院上海药物研究所 一种酰胺类化合物、其药物组合物及其制备方法和用途
EP2456309B1 (en) * 2009-07-24 2015-12-23 GlaxoSmithKline LLC Azabicyclo[3.2.1]octyl derivatives for use in the treatment of HIV.
CN102140104B (zh) * 2010-02-03 2014-11-12 中国科学院上海药物研究所 1-(3-(s)-氨基丙基)-哌啶-4-氨基酰胺类化合物、其药物组合物及其制备方法和用途
MX2012011415A (es) 2010-04-02 2013-02-26 Phivco 1 Llc Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico.
CN103159754A (zh) * 2011-12-19 2013-06-19 中国科学院上海药物研究所 一种氨基丙基取代托烷胺类化合物、其药物组合物及其制备方法和用途
WO2014068265A1 (en) 2012-10-29 2014-05-08 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
CZ306455B6 (cs) 2013-04-26 2017-02-01 Zentiva, K.S. Nový způsob syntézy Maravirocu
CN103497164B (zh) * 2013-09-23 2015-12-23 西安近代化学研究所 一种蒽衍生物及其制备方法
CN104304248B (zh) * 2014-10-23 2016-08-10 西北农林科技大学 3-芳基丙酸酯类化合物作为制备杀螨药物的应用
CN104402883B (zh) * 2014-10-24 2016-04-27 艾琪康医药科技(上海)有限公司 4,4-二氟金刚烷甲酰胺衍生物、药物组合物及其制备方法和用途
CN104387379B (zh) * 2014-11-26 2017-01-11 扬州氟药科技有限公司 一种二氟亚甲基哌啶甲酰胺衍生物及其制备方法和用途
CN104860946A (zh) * 2015-05-14 2015-08-26 湖北生物医药产业技术研究院有限公司 Ccr5拮抗剂的制备方法
CN107879963A (zh) 2016-09-29 2018-04-06 中国科学院上海药物研究所 新型手性配体、金属螯合物、多种非天然氨基酸、马拉维诺及其关键中间体的合成方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5648511A (en) * 1990-11-19 1997-07-15 G.D. Searle & Co. Method for making intermediates useful in the synthesis of retroviral protease inhibitors
FR2676444B1 (fr) * 1991-05-16 1995-03-10 Sanofi Elf Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
EE03877B1 (et) * 1994-04-19 2002-10-15 Neurosearch A/S Tropaan-2-aldoksiimi derivaadid neurotransmitteritagasihaarde inhibiitoritena
GB9523526D0 (en) * 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
DE19546462A1 (de) * 1995-12-13 1997-06-19 Bayer Ag Diarylacetylenketone
AU1208397A (en) * 1995-12-28 1997-07-28 Takeda Chemical Industries Ltd. Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
US6323206B1 (en) * 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6281212B1 (en) * 1996-07-12 2001-08-28 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
AU5604998A (en) * 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1998025617A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CA2296314A1 (en) * 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
WO1999037619A1 (en) * 1998-01-21 1999-07-29 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
EP1013276A1 (en) 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
US7217714B1 (en) * 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
HRP20020938B1 (en) * 2000-05-26 2011-05-31 Pfizer Inc. Tropane derivatives useful in therapy

Also Published As

Publication number Publication date
CN1437599A (zh) 2003-08-20
JP4854970B2 (ja) 2012-01-18
EE200200656A (et) 2004-06-15
NO20025227L (no) 2002-10-31
CY2022009I1 (el) 2022-05-27
HUP0302474A3 (en) 2007-05-29
EA005382B1 (ru) 2005-02-24
RS51436B (sr) 2011-04-30
HK1054927A1 (en) 2003-12-19
NL300338I2 (nl) 2008-06-02
HRP20020938B1 (en) 2011-05-31
NO2010007I2 (no) 2013-09-09
EG24137A (en) 2008-08-06
KR100523501B1 (ko) 2005-10-25
CZ20023806A3 (cs) 2004-01-14
ME00555B (me) 2011-12-20
PA8517101A1 (es) 2002-10-24
HK1078573A1 (en) 2006-03-17
JP2005194283A (ja) 2005-07-21
AU2001252482C1 (en) 2001-12-03
NZ521477A (en) 2004-07-30
NO327892B1 (no) 2009-10-12
IS2511B (is) 2009-05-15
HRP20020938A2 (en) 2005-02-28
DE60102233T2 (de) 2005-01-27
DE122008000011I1 (de) 2008-06-05
EA007580B1 (ru) 2006-12-29
LU91417I9 (es) 2019-01-02
TR200400541T4 (tr) 2004-04-21
MXPA02011631A (es) 2003-03-27
ME00555A (en) 2011-12-20
DE60135685D1 (de) 2008-10-16
EA200401056A1 (ru) 2005-04-28
ES2215129T3 (es) 2004-10-01
GEP20063799B (en) 2006-04-25
BG65966B1 (bg) 2010-07-30
BR0110955A (pt) 2003-06-03
YU82202A (sh) 2005-11-28
DE60102233D1 (de) 2004-04-08
CN100355753C (zh) 2007-12-19
TNSN01077A1 (fr) 2005-11-10
EP1990341B1 (en) 2013-01-23
BRPI0110955B1 (pt) 2016-06-28
PL359267A1 (en) 2004-08-23
CN1279040C (zh) 2006-10-11
BG107140A (bg) 2003-05-30
WO2001090106A3 (en) 2002-03-28
CA2408909C (en) 2006-06-27
WO2001090106A2 (en) 2001-11-29
SI1284974T1 (en) 2004-08-31
EP1526134B1 (en) 2008-09-03
CN1680371A (zh) 2005-10-12
MY131019A (en) 2007-07-31
UY26727A1 (es) 2001-12-28
CY2008006I1 (el) 2009-11-04
ATE260914T1 (de) 2004-03-15
PT1526134E (pt) 2008-10-28
KR100548854B1 (ko) 2006-02-02
AP2002002663A0 (en) 2002-12-31
MA26902A1 (fr) 2004-12-20
NO2010007I1 (no) 2010-04-08
HK1090836A1 (en) 2007-01-05
OA12264A (en) 2003-11-10
NL300338I1 (nl) 2008-05-01
MY153023A (en) 2014-12-31
CY2008006I2 (el) 2009-11-04
JP3693957B2 (ja) 2005-09-14
DZ3464A1 (es) 2001-11-29
TWI230160B (en) 2005-04-01
EP1526134A3 (en) 2006-11-29
HU225810B1 (en) 2007-10-29
RS20090438A (sr) 2010-05-07
BRPI0110955B8 (pt) 2021-05-25
LTPA2008004I1 (lt) 2020-07-27
AP1965A (en) 2009-03-04
IL152531A0 (en) 2003-05-29
CZ299102B6 (cs) 2008-04-23
KR20030004417A (ko) 2003-01-14
LU91417I2 (fr) 2008-04-22
PE20011371A1 (es) 2002-01-18
CA2408909A1 (en) 2001-11-29
FR08C0007I2 (fr) 2009-01-15
EP1284974B1 (en) 2004-03-03
CR10145A (es) 2008-08-19
JP2003534343A (ja) 2003-11-18
EP1526134A2 (en) 2005-04-27
EE05110B1 (et) 2008-12-15
ATE407134T1 (de) 2008-09-15
IS6565A (is) 2002-09-24
FR08C0007I1 (es) 2008-04-25
ES2311126T3 (es) 2009-02-01
SI1526134T1 (sl) 2008-12-31
EA200201141A1 (ru) 2003-04-24
DK1284974T3 (da) 2004-06-07
SK16432002A3 (sk) 2004-01-08
HUP0302474A2 (hu) 2003-11-28
AU2001252482B2 (en) 2006-01-19
CY2022009I2 (el) 2022-05-27
PL200551B1 (pl) 2009-01-30
NO20025227D0 (no) 2002-10-31
AU5248201A (en) 2001-12-03
SK286129B6 (sk) 2008-04-07
IL152531A (en) 2010-05-17
KR20050046743A (ko) 2005-05-18
AR028622A1 (es) 2003-05-14
CY1108451T1 (el) 2014-04-09
DK1526134T3 (da) 2008-11-17
NO2020019I1 (no) 2020-06-30
ES2401812T3 (es) 2013-04-24
AR060159A2 (es) 2008-05-28
MY156920A (en) 2016-04-15
EP1284974A2 (en) 2003-02-26
EP1990341A1 (en) 2008-11-12
PT1284974E (pt) 2004-06-30
RS50904B (sr) 2010-08-31
LTC1284974I2 (lt) 2020-11-10

Similar Documents

Publication Publication Date Title
UY26727A1 (es) Derivados de tropano útiles en terapia
UY28026A1 (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos.
ES2188957T3 (es) N-(4-(heteroarilmetil)fenil)-heteroarilaminas.
CR7069A (es) Derivados de pirazol para el tratamiento de vih
PA8518801A1 (es) Derivados de 2-aminocarbonil-9h-purina
MXPA03002839A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7.
PA8547901A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
AR043111A1 (es) Derivados monoacilados de o-fenilendiaminas
ECSP077185A (es) Derivados de piridina
ES2188016T3 (es) Derivaqdo de benzamidoxima, productos intermedios y procedimiento para su obtencion y su empleo como fungicidas.
UY27446A1 (es) Nuevos compuestos
UY29437A1 (es) Nuevos antagonistas de cgrp
AR049883A1 (es) Antagonistas de cgrp seleccionados, procedimientos para su preparacion, y su empleo como medicamentos
DK1485377T5 (da) Pyranoner egnede som ATM-inhibitorer
CO5550439A2 (es) Compuestos derivados de arilsulfonil-piperazina que tienen afinidad al receptor 5-ht6 y composiciones farmaceuticas que los contienen
AR035110A1 (es) Compuesto derivado de piperazina, uso del mismo para la preparacion de una composicion farmaceutica, composicion farmaceutica que lo comprende y procedimiento para la preparacion de dicho compuesto
AR044453A1 (es) Derivados de metoxi-pirazin-tienil sulfonamida
AR044275A1 (es) Uso de derivados de sulfonamidas para la fabricacion de un medicamento para la profilaxis y/o tratamiento de las disfunciones alimentarias
ES2189072T3 (es) Nuevo benzo-cicloalquenos heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
UY29749A1 (es) Antagonistas de cgrp seleccionados, procedimientos para su preparación, así como su uso como medicamentos
SV1999000075A (es) Derivados de 3-(2-oxo-[1,3&#39;]bipirrolidinil-3-ilidenemetil)-cefemos
AR035247A1 (es) Derivados de piperidinacarboxamida, un procedimiento para su preparacion y las composiciones farmaceuticas que los contienen
ECSP014089A (es) Derivados de tropano utiles en terapia
CR9072A (es) 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-7-etinil-3-quinolinocarbonitrilos para el tratamiento de lesion isquemica
EA200301171A1 (ru) Новые соединения трициклических дигидрохинолинов, способ их получения и фармацевтические композиции, содержащие их